Search

Your search keyword '"Brasó-Maristany F"' showing total 18 results
Start Over Author "Brasó-Maristany F" Journal esmo open
18 results on '"Brasó-Maristany F"'

1. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

Author

Schettini, F., Nucera, S., Brasó-Maristany, F., De Santo, I., Pascual, T., Bergamino, M., Galván, P., Conte, B., Seguí, E., García Fructuoso, I., Gómez Bravo, R., Rivera, P., Rodríguez, A.B., Martínez-Sáez, O., Ganau, S., Sanfeliu, E., González-Farre, B., Vidal Losada, M.J., Adamo, B., Cebrecos, I., Mension, E., Oses, G., Jares, P., Vidal-Sicart, S., Mollà, M., Muñoz, M., and Prat, A.

Published
2024
Full Text
View/download PDF

2. Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network—Breast dataset (SCAN-B)

Author

Villacampa, G., Pascual, T., Brasó-Maristany, F., Paré, L., Martínez-Sáez, O., Cortés, J., Ciruelos, E., Martin, M., Conte, P., Carey, L.A., Fernandez, A., Harbeck, N., Marín-Aguilera, M., Vivancos, A., Curigliano, G., Villagrasa, P., Parker, J.S., Perou, C.M., Prat, A., and Tolaney, S.M.

Published
2024
Full Text
View/download PDF

3. Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer

Author

Marín-Aguilera, M., Jares, P., Sanfeliu, E., Villacampa, G., Hernández-lllán, E., Martínez-Puchol, A.I., Shankar, S., González-Farré, B., Waks, A.G., Brasó-Maristany, F., Pardo, F., Manning, D.K., Abery, J.A., Curaba, J., Moon, L., Gordon, O., Galván, P., Wachirakantapong, P., Castillo, O., Nee, C.M., Blasco, P., Senevirathne, T.H., Sirenko, V., Martínez-Sáez, O., Aguirre, A., Krop, I.E., Li, Z., Spellman, P., Metzger Filho, O., Polyak, K., Michaels, P., Puig-Butillé, J.A., Vivancos, A., Matito, J., Buckingham, W., Perou, C.M., Villagrasa-González, P., Prat, A., Parker, J.S., and Paré, L.

Published
2024
Full Text
View/download PDF

6. 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial

Author

Oliveira, M., primary, Pascual, T., additional, Ortega, P. Tolosa, additional, Vila, M. Margeli, additional, Cejalvo, J.M., additional, Jurado, J. Cruz, additional, Bofill, F.J. Salvador, additional, Arumi de Dios, M.A., additional, Losada, M.J. Vidal, additional, Simon, S. Pernas, additional, Esker, S., additional, Fan, P-D., additional, Santhanagopal, A., additional, Martínez-Sáez, O., additional, Brasó-Maristany, F., additional, Villacampa, G., additional, Bayona, R. Sanchez, additional, Ferrero-Cafiero, J.M., additional, Falato, C., additional, and Prat, A., additional

Published
2023
Full Text
View/download PDF

7. 3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial

Author

Brasó-Maristany, F., primary, Oliveira, M., additional, Ortega, P. Tolosa, additional, Vila, M. Margeli, additional, Jurado, J. Cruz, additional, Bofill, F.J. Salvador, additional, Cejalvo, J.M., additional, Arumi de Dios, M.A., additional, Losada, M.J. Vidal, additional, Simon, S. Pernas, additional, Esker, S., additional, Fan, P-D., additional, Santhanagopal, A., additional, Saez, O. Martinez, additional, Villacampa, G., additional, Bayona, R. Sanchez, additional, Ferrero-Cafiero, J.M., additional, Falato, C., additional, Pascual, T., additional, and Prat, A., additional

Published
2023
Full Text
View/download PDF

8. 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)

Author

Schettini, F., primary, Pascual, T., additional, Ghiglione, L., additional, Brasó-Maristany, F., additional, Martínez-Sáez, O., additional, Conte, B., additional, Cebrecos, I., additional, Mension, E., additional, Ganau, S., additional, Torres, E. Sanfeliu, additional, Gonzalez-Farre, B., additional, Jares, P., additional, Vidal-Siscart, S., additional, Mollá, M., additional, Adamo, B., additional, Losada, M.J. Vidal, additional, Munoz, M., additional, and Prat, A., additional

Published
2023
Full Text
View/download PDF

9. 7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer

Author

Torres, E. Sanfeliu, primary, Villacampa, G., additional, Pascual, T., additional, Oliveira, M., additional, Losada, M.J. Vidal, additional, Bellet-Ezquerra, M., additional, Gonzalez-Farre, B., additional, Puig-Butille, J.A., additional, Jares, P., additional, Simon, S. Pernas, additional, Muiño, C. Bueno, additional, Jimenez, M. Martin, additional, Tarantino, P., additional, Waks, A.G., additional, Mittendorf, E.A., additional, Tolaney, S.M., additional, Cortés, J., additional, Cussac, A. Llombart, additional, Prat, A., additional, and Brasó-Maristany, F., additional

Published
2023
Full Text
View/download PDF

10. 102P HER2DX risk-score in early-stage HER2-positive (HER2+) breast cancer: A correlative analysis of 757 patients from the Sweden Cancerome Analysis Network - Breast (SCAN-B) dataset

Author

Pascual, T., primary, Villacampa, G., additional, Brasó-Maristany, F., additional, Brunet, L. Pare, additional, Saez, O. Martinez, additional, Cortés, J., additional, Ciruelos, E.M., additional, Jimenez, M. Martin, additional, Conte, P.F., additional, Carey, L.A., additional, Fernandez-Martinez, A., additional, Harbeck, N., additional, Marín-Aguilera, M., additional, Vivancos, A., additional, Curigliano, G., additional, Gonzalez, P. Villagrasa, additional, Parker, J., additional, Tolaney, S.M., additional, Perou, C.M., additional, and Prat, A., additional

Published
2023
Full Text
View/download PDF

11. 12P HER2DX in HER2-positive (HER2+) inflammatory breast cancer (IBC): A correlative analysis from a phase II clinical trial

Author

Lynce, F., primary, Brasó-Maristany, F., additional, Waks, A.G., additional, Gonzalez, P. Villagrasa, additional, Villacampa, G., additional, Torres, E. Sanfeliu, additional, Galván, P., additional, Brunet, L. Pare, additional, Anderson, L., additional, Perou, C.M., additional, Parker, J., additional, Vivancos, A., additional, Dilullo, M., additional, Simon, S. Pernas, additional, Winer, E.P., additional, Overmoyer, B., additional, Mittendorf, E.A., additional, Prat, A., additional, and Tolaney, S.M., additional

Published
2023
Full Text
View/download PDF

12. 11P Independent validation of the HER2DX assay in HER2-positive (HER2+) breast cancer (BC) treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): A correlative analysis from the BiOnHER study

Author

Grimalt, B. Fullana, primary, Brasó-Maristany, F., additional, Gómez, N., additional, Petit, A., additional, Ortega, R., additional, Vicente, M., additional, Falo, C., additional, Stradella, A., additional, Vazquez, S., additional, Vazquez, R. Villanueva, additional, Pla, M.J., additional, Purqueras, E., additional, Calaf, M., additional, Brunet, L. Pare, additional, Marín-Aguilera, M., additional, Galván, P., additional, Perou, C.M., additional, Gonzalez, P. Villagrasa, additional, Prat, A., additional, and Simon, S. Pernas, additional

Published
2023
Full Text
View/download PDF

13. 5P HER2DX risk-score in HER2-positive (HER2+) breast cancer following neoadjuvant and adjuvant anti-HER2-based treatment: An updated survival analysis

Author

Saez, O. Martinez, primary, Brasó-Maristany, F., additional, Griguolo, G., additional, Brunet, L. Pare, additional, Dieci, M.V., additional, Cortés, J., additional, Cussac, A. Llombart, additional, Villacampa, G., additional, Marín-Aguilera, M., additional, Rey, M., additional, Goberna, G., additional, Munoz, M., additional, Vivancos, A., additional, Gonzalez, P. Villagrasa, additional, Parker, J., additional, Conte, P.F., additional, Prat, A., additional, Pascual, T., additional, and Guarneri, V., additional

Published
2023
Full Text
View/download PDF

14. 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

Author

Saez, O. Martinez, primary, Brasó-Maristany, F., additional, Marín-Aguilera, M., additional, Losada, M.J. Vidal, additional, Adamo, B., additional, Pascual, T., additional, Schettini, F., additional, Conte, B., additional, Chic, N., additional, Bravo, R. Gomez, additional, Fructuoso, I. Garcia, additional, Solis, E. Segui, additional, Galván, P., additional, Hernández-Illán, E., additional, Jares, P., additional, Puig-Butille, J.A., additional, Torres, E. Sanfeliu, additional, Brunet, L. Pare, additional, Gonzalez, P. Villagrasa, additional, and Munoz, M., additional

Published
2023
Full Text
View/download PDF

15. 126MO HER2DX and pathological complete response in HER2-positive breast cancer: A combined analysis of 4 neoadjuvant studies

Author

Waks, A.G., primary, Villacampa, G., additional, Brunet, L. Pare, additional, Tung, N.M., additional, Muiño, C. Bueno, additional, Diaz-Guardamino, I. Echavarria, additional, Lopez-Tarruella Cobo, S., additional, Marín-Aguilera, M., additional, Brasó-Maristany, F., additional, Pascual, T., additional, Saez, O. Martinez, additional, Wolff, A.C., additional, Demichele, A., additional, Perou, C.M., additional, Fernandez-Martinez, A., additional, Carey, L.A., additional, Mittendorf, E.A., additional, Jimenez, M. Martin, additional, Prat, A., additional, and Tolaney, S.M., additional

Published
2023
Full Text
View/download PDF

16. 10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)

Author

Morganti, S., primary, Brasó-Maristany, F., additional, Rey, M., additional, Goberna, G., additional, Pascual, T., additional, Schettini, F., additional, Conte, B., additional, Bravo, R. Gomez, additional, Fructuoso, I. Garcia, additional, Solis, E. Segui, additional, Galván, P., additional, Torres, E. Sanfeliu, additional, Gonzalez-Farre, B., additional, Losada, M.J. Vidal, additional, Adamo, B., additional, Munoz, M., additional, Lin, N., additional, Tolaney, S.M., additional, Prat, A., additional, and Saez, O. Martinez, additional

Published
2023
Full Text
View/download PDF

17. 6P Combined analysis of the HER2DX genomic tool in adjuvant APT and ATEMPT trials

Author

Tarantino, P., primary, Villacampa, G., additional, Graham, N., additional, Waks, A.G., additional, Gonzalez, P. Villagrasa, additional, Brasó-Maristany, F., additional, Torres, E. Sanfeliu, additional, Galván, P., additional, Brunet, L. Pare, additional, Demeo, M.K., additional, Partridge, A.H., additional, Burstein, H.J., additional, Krop, I., additional, Tayob, N., additional, Winer, E.P., additional, Prat, A., additional, and Tolaney, S.M., additional

Published
2023
Full Text
View/download PDF

18. 13P Analytical validation of HER2DX test for early-hER2+ breast cancer

Author

Torres, E. Sanfeliu, primary, Marín-Aguilera, M., additional, Jares, P., additional, Villacampa, G., additional, Hernández-Illán, E., additional, Gonzalez-Farre, B., additional, Brasó-Maristany, F., additional, Galván, P., additional, Castillo, O., additional, Blasco, P., additional, Sirenko, V., additional, Aguirre, Á., additional, Puig-Butille, J.A., additional, Vivancos, A., additional, Matito, J., additional, Perou, C.M., additional, Gonzalez, P. Villagrasa, additional, Prat, A., additional, Parker, J., additional, and Brunet, L. Pare, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results